This is a working overview of purity certificate, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-22 and is reviewed periodically as new material appears.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
== Gene location of IDDM == Genome-wide linkage analysis could be used for identification in susceptibility genes of insulin-dependent (type I) diabetes mellitus (IDDM). This analysis verifies that eighteen different genome regions are predisposed to insulin-dependent (type I) diabetes mellitus(IDDM). There are 18 different symbols of genome region, which is labeled from IDDM1 to IDDM18. The MHC HLA gene (IDDM1) and the insulin gene INS (IDDM2) are the major genetic candidates in the development of insulin-dependent (type I) diabetes mellitus(IDDM), which are located on the chromosome 6p21.3 and chromosome 11p15 respectively. IDDM3, IDDM4, IDDM5 IDDM7 reside in chromosome 15q26, chromosome 11q13, chromosome 6q25 and 2q31 respectively.IDDM11 (insulin-dependent diabetes mellitus 11) is one of the susceptibility genes for IDDM which locates on chromosome 14q24.3-q31. This loci is identified by linkage to D14S67 marker via a sibling-pair linkage analysis Based on the previous study, the biological behavior of IDDM11is different to HLA region genes so that IDDM11 is less predisposing to HLA. Moreover, IDDM11 has more involvement on the families that are less predisposing to HLA, while IDDM11 has less involvement on the families that are more predisposing to HLA. The rest of susceptibility genes locus in insulin-dependent (type I) diabetes mellitus (IDDM)are shown in table 1. Table 1 The locus for susceptibility genes for IDDM.
Ribosome profiling, or Ribo-Seq (also named ribosome footprinting), is an adaptation of a technique developed by Joan Steitz and Marilyn Kozak almost 50 years ago that Nicholas Ingolia and Jonathan Weissman adapted to work with next generation sequencing that uses specialized messenger RNA (mRNA) sequencing to determine which mRNAs are being actively translated. A related technique that can also be used to determine which mRNAs are being actively translated is the Translating Ribosome Affinity Purification (TRAP) methodology, which was developed by Nathaniel Heintz at Rockefeller University (in collaboration with Paul Greengard and Myriam Heiman). TRAP does not involve ribosome footprinting but provides cell type-specific information.
Cure T1D by restoring the body’s ability to produce insulin and stopping T1D before it occurs or providing insulin independence through replacement with insulin-producing cells. Improve lives by minimizing the effects of T1D as much as possible until new T1D resources, technologies, and therapies are discovered. Breakthrough T1D prioritizes four strategic research areas; autoimmune therapies, cell therapies, prevention of complications, and glucose control.
== Clinical significance == Parenteral (intravenous) administration of glucagon is a common human medical intervention in diabetic emergencies when sugar cannot be given orally. It can also be administered intramuscularly.
Sources: en.wikipedia.org
=== Lozano-Fernandez et al. (2019) === In 2019, similar to previous studies, such as Oakley et al. (2013) and Schwentner et al. (2017), Lozano-Fernandez et al. divided Pancrustacea into Allotriocarida, along with Oligostraca and Multicrustacea, as the three main divisions of subphylum Pancrustacea, embracing the traditional crustaceans and the hexapods (including insects). Lozano-Fernandez et al. also proposed a new group Athalassocarida for the Labiocarida plus Branchiopoda clade (derived from "Athalasso" [Greek: nonmarine] and "carida" [Greek: prawn]), thereby referring to a grouping of pancrustaceans where all extant members either live in nonmarine settings or reverted to a marine life-style secondarily.
Aminoacylase is a metallo-enzyme that needs Zinc (Zn2+) as a cofactor to function. The Zinc ions inside of aminoacylase are each coordinated to histidine, glutamate, aspartate, and water. The Zinc ion polarizes the water, facilitating its deprotonation by a nearby basic residue. The negatively charged hydroxide ion is nucleophilic and attacks the electrophilic carbonyl carbon of the substrate's acyl group. The exact mechanism after this point is unknown, with one possibility being that the carbonyl then reforms, breaks the amide bond, and forms the two products. At some point in the mechanism, another water molecule enters and coordinates with Zinc, returning the enzyme to its original state.
Naturally occurring xenon (54Xe) consists of nine isotopes: seven stable isotopes and two very long-lived radioactive isotopes: double electron capture has been observed in 124Xe (half-life 1.1 ± 0.2stat ± 0.1sys×1022 years), and double beta decay in 136Xe (half-life 2.18 ×1021 years), which are among the longest measured half-lives of all nuclides. The isotopes 126Xe and 134Xe are also predicted to undergo double beta decay, but such decay processes have not been observed. Artificial unstable isotopes have been prepared from 108Xe to 150Xe, the longest-lived of which is 127Xe with a half-life of 36.342 days. All other nuclides have half-lives less than 12 days, most less than one hour. The shortest-lived isotope, 108Xe, has a half-life of 58 μs, and is the heaviest known nuclide with equal numbers of protons and neutrons. Of known isomers, the longest-lived is 131mXe with a half-life of 11.95 days, the second longest of all xenon's nuclides. 129Xe is produced by beta decay of natural or artificial 129I (half-life 16.1 million years); 131mXe, 133Xe, 133mXe, and 135Xe are some of the fission products of both 235U and 239Pu, so are used as indicators of nuclear explosions. The artificial isotope 135Xe is of considerable significance in the operation of nuclear fission reactors. 135Xe has a huge cross section for thermal neutrons, 2.65 million barns, so it acts as a neutron absorber or "poison" that can slow or stop the chain reaction after a period of operation.
18 Poems, The Sunday Referee; Parton Bookshop, 1934 Portrait of the Artist as a Young Dog, London: Dent, 1940 Deaths and Entrances, London: Dent, 1946 A Child's Christmas in Wales, New Directions, 1955 The Collected Poems of Dylan Thomas: The New Centenary Edition. Ed. with Introduction and annotations by John Goodby. London: Weidenfeld & Nicolson, 2014 The Notebook Poems 1930–34, ed. Ralph Maud. London: Dent, 1989 Dylan Thomas: The Broadcasts, ed. Ralph Maud. London: Dent, 1991 Dylan Thomas: The Filmscripts, ed. John Ackerman. London: Dent, 1995 Dylan Thomas: Early Prose Writings, ed. Walford Davies. London: Dent, 1971 Collected Stories, ed. Walford Davies. London: Dent, 1983 Under Milk Wood: A Play for Voices, ed. Walford Davies and Ralph Maud. London: Dent, 1995 On the Air with Dylan Thomas: The Broadcasts, ed. R. Maud. New York: New Directions, 1991
Holyhead's arts centre, the Ucheldre Centre, is located in the chapel of an old convent belonging to the order of the Bon Sauveur. It holds regular art exhibitions, performances, workshops and film screenings. Holyhead Library is located in the old market hall. The Holyhead Maritime Museum is housed in what is claimed to be Wales's oldest lifeboat house. The lifeboat station was established in 1828. The 1927 National Eisteddfod was held in the town. Holyhead High School (previously County Secondary school) was the first comprehensive school in the UK. According to the United Kingdom Census 2001, 47% of the residents in the town can speak Welsh. The highest percentage of speakers is in the 15-year-old age group, of whom 66% can speak the language. According to the 2011 Census, of those in the community who were born in Wales, 52.2% of the population could speak Welsh. The town's main football team is called Holyhead Hotspur, and they play in the Cymru North, the second tier of Welsh football, with their reserves playing in the Gwynedd League. Caergybi F.C. plays in the sixth tier Anglesey League. Holyhead Sailing Club provides members with facilities for sailing and kayaking with swinging moorings, a dinghy park and a clubhouse with a restaurant and bar. It is on Newry Beach in the historic port of Holyhead. Holyhead & Anglesey Amateur Boxing Club was founded on 1 April 2012, located in Vicarage Lane, Holyhead. The club is open to anyone over the age of 10, having a class for male and female trainees.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.